Company: BLRX
Filing Date: 2025-01-07
Form Type: 424B5
Source: 0001178913-25-000045
Chunk: 10

Company: BioLineRx Ltd.
Filing Date: 2025-01-07
Form: 424B5
Chunk 10
---
 exercise of warrants to be issued to the investors in this offering, at an exercise price of $0.20 per ADS; and |

| • | 37,500,000 ordinary shares represented by 2,500,000 ADSs issuable upon exercise of warrants to be issued to the placement agent or its designees as compensation in connection with this offering, at an exercise price of $0.25 per ADS. |

Except as otherwise indicated, all information in this prospectus supplement assumes no exercise of outstanding options and warrants. S - 4 RISK FACTORS An investment in our securities involves a high degree of risk, you should carefully consider the risk factors set forth in our most recent Annual Report on Form 20-F, which are incorporated by reference into this prospectus supplement, as well as the following risk factors, which supplement or augment the risk factors set forth in our most recent Annual Report on Form 20-F. Before making an investment decision, you should carefully consider these risks as well as other information we include or incorporate by reference in this prospectus supplement. The risks and uncertainties not presently known to us or that we currently deem immaterial may also materially harm our business, operating results and financial condition and could result in a complete loss of your investment. Risks Related to this Offering Management has broad discretion as to the use of proceeds of this offering, and we may not use these proceeds in a manner desired by our shareholders. Our management will have broad discretion as to the use of the net proceeds from this offering and could use them for purposes other than those contemplated at the time of this offering. Accordingly, you will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity as part of your investment decision to assess whether the proceeds are used appropriately. Our needs may change as our business evolves. As a result, the proceeds to be received in this offering may be used significantly differently than currently expected at the time of this offering. It is possible that the proceeds will be used in a way that does not yield a favorable, or any, return. You will experience immediate dilution in book value of any ADSs you purchase. Because the price per ADS or pre-funded warrant and associated warrant being offered is substantially higher than our net tangible book value per ADS, you will suffer substantial dilution in the net tangible book value of any ADSs or pre-funded warrants you purchase in this offering. After giving effect to the sale by us of 34,332,122